Symptomatic effect of a long acting Lanreotide formulation in patients with gastrointestinal neuroendocrine tumours.

被引：0
|
作者：
Jacobsen, MB [1 ]
deVries, EGE [1 ]
Eriksson, B [1 ]
Fiasse, R [1 ]
Wijmenga, M [1 ]
Salmela, P [1 ]
Valimaki, M [1 ]
Oberg, K [1 ]
Renstrup, J [1 ]
机构：
[1] UNIV OSLO, OSLO, NORWAY
来源：
GASTROENTEROLOGY | 1996年 / 110卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A535 / A535
页数：1
相关论文
共 50 条
  • [41] PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF A LONG-ACTING FORMULATION OF THE NEW SOMATOSTATIN ANALOG, LANREOTIDE, IN NORMAL HEALTHY-VOLUNTEERS
    KUHN, JM
    LEGRAND, A
    RUIZ, JM
    OBACH, R
    DERONZAN, J
    THOMAS, F
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (03) : 213 - 219
  • [42] Phase II trial of the long acting somatostatin analogue lanreotide in patients with advanced hepatocellular cancer
    Hejna, M
    Kornek, GV
    Raderer, M
    Valencak, J
    Lehnauer, B
    Fiebiger, W
    Greul, R
    Lang, F
    Schneeweiss, B
    Depisch, D
    Scheithauer, W
    BRITISH JOURNAL OF CANCER, 1998, 78 : 36 - 36
  • [43] Treatment of gastro-entero-pancreatic (GEP) neuroendocrine tumors with lanreotide, a new-long-acting somatostatin analogue.
    Migliori, M
    Tomassetti, P
    Montini, GC
    Lalli, S
    Corinaldesi, R
    GASTROENTEROLOGY, 1998, 114 (04) : A643 - A643
  • [44] Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation
    Aalbersberg, E. A.
    de Wit-van der Veen, B. J.
    Versleijen, M. W. J.
    Saveur, L. J.
    Valk, G. D.
    Tesselaar, M. E. T.
    Stokkel, M. P. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (03) : 696 - 703
  • [45] Phase II trial of the long acting somatostatin analogue lanreotide in patients with advanced hepatocellular cancer
    Hejna, M
    Kornek, GV
    Raderer, M
    Valencak, J
    Lehnauer, B
    Fiebiger, W
    Greul, R
    Lang, F
    Schneeweiss, B
    Depisch, D
    Scheithauer, W
    ANNALS OF ONCOLOGY, 1998, 9 : 175 - 175
  • [46] PREDICTORS OF ANTIPROLIFERATIVE EFFECT OF LANREOTIDE AUTOGEL AS FIRST-LINE THERAPY FOR ADVANCED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOURS (GEP NET)
    Laskaratos, Faidon-Marios
    Megapanou, Maria
    Papantoniou, Dimitrios
    Hayes, Aimee R.
    von Stempel, Conrad
    Phillips, Edward
    Furnace, Myles
    Kousteni, Margarita
    Shah, Heer
    Mandair, Dalvinder
    Caplin, Martyn
    Toumpanakis, Christos
    GASTROENTEROLOGY, 2018, 154 (06) : S197 - S197
  • [47] Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism
    Corda, Heike
    Kummer, Sebastian
    Welters, Alena
    Teig, Norbert
    Klee, Dirk
    Mayatepek, Ertan
    Meissner, Thomas
    ORPHANET JOURNAL OF RARE DISEASES, 2017, 12
  • [48] Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism
    Heike Corda
    Sebastian Kummer
    Alena Welters
    Norbert Teig
    Dirk Klee
    Ertan Mayatepek
    Thomas Meissner
    Orphanet Journal of Rare Diseases, 12
  • [49] Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation
    E. A. Aalbersberg
    B. J. de Wit – van der Veen
    M. W. J. Versleijen
    L. J. Saveur
    G. D. Valk
    M. E. T. Tesselaar
    M. P. M. Stokkel
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 696 - 703
  • [50] Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies
    Phan, A. T.
    Wolin, E. M.
    Fisher, G. A.
    Ruszniewski, P.
    Pavel, M.
    Liyanage, N.
    Mirakhur, B.
    Braun, S.
    Caplin, M.
    Vinik, A., I
    NEUROENDOCRINOLOGY, 2017, 105 : 206 - 206
12345